Back to search
Invasive Pulmonary Fungal Disease
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Invasive Pulmonary Fungal Disease trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Invasive Pulmonary Fungal Disease trials you may qualify forTo evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
Aspergillus fumigatus PCR is currently used in conjunction with serum galactomannan to support the diagnosis of invasive aspergillosis or for monitoring at-risk…
This trial is aimed to study the immunological and pathological characteristics of influenza versus non-influenza severe community-acquired pneumonia patients i…
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and m…
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management…
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (P…
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared…